Shareholders approve all proposals at annual meeting including 5.2M share increase to equity plan

Xenon Pharmaceuticals Inc.

All 8 director nominees elected, e.g., Dawn Svoronos 61.5M For vs 4.5M Against; broker non-votes 2.6M.
Say-on-pay advisory vote approved: 64.0M For, 2.0M Against, 0.01M abstain.
Equity plan amendments approved to increase share reserve by 5,200,000 common shares: 63.1M For, 2.8M Against.
KPMG LLP appointed as independent auditor for 2024: 66.7M For, 1.8M Withheld.
Auditor remuneration authority approved: 65.7M For, 0.39M Against, 0.01M Abstain.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.